Concepedia

Publication | Closed Access

Real-life data on efficacy and safety of original Adalimumab and biosimilar Adalimumab (ABP 501) in pediatric rheumatic diseases

DOI

10

Citations

18

References

2022

Year

Kadir Ulu, Mustafa Çakan, Şengül Çağlayan, Ramazan Emre Yiğit, Ferhat Demir, Taner Çoşkuner, Esra Kardeş, Betül Sözeri
Expert Opinion on Biological Therapy

Abstract

There was no significant difference between the biosimilar and the original product in efficacy and safety.

References

YearCitations

Page 1